Natural Alternatives International, Inc. — Form 10-Q Summary
Reporting-period clarification: The request identifies “2015 Q3,” but the filing covers the quarter and nine months ended March 31, 2016 (fiscal 2016 Q3). Amounts below are in U.S. dollars; financial statement amounts are shown in millions unless stated otherwise.
Business context and period
NAI manufactures private-label nutritional products and earns revenue from beta-alanine (CarnoSyn) sales and related patent and trademark licensing. The filing reports unaudited consolidated results. NAI shifted in April 2015 from a third-party distribution arrangement to direct beta-alanine sales and distribution. Its Pathway to Healing branded product line had been discontinued.
Key financial results
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net sales | $30.0m; +53% year over year | $78.5m; +38% |
| Gross profit / margin | $6.5m / 21.5%, versus $3.7m / 18.7% | $16.9m / 21.5%, versus $10.4m / 18.4% |
| Operating income / margin | $3.1m / 10.3%, versus $1.0m / 5.3% | $7.6m / 9.6%, versus $3.0m / 5.3% |
| Net income | $3.0m, versus $0.8m | $6.1m, versus $2.4m |
| Diluted EPS | $0.46, versus $0.12 | $0.92, versus $0.35 |
For the nine months, private-label contract manufacturing sales rose 21% to $62.4m, while patent and trademark licensing segment sales rose to $16.1m from $4.7m. The latter increase reflected direct beta-alanine raw material sales; the prior-year period primarily included royalties. Branded-product sales were nil, down from $0.7m.
Operating cash flow was $2.4m for the nine months, compared with $2.2m. Capital expenditures were $7.0m, partly offset by $3.0m of proceeds from asset sales; investing activities used $4.0m. Cash declined to $16.3m from $18.6m at June 30, 2015. Inventory increased to $19.7m from $12.6m, and accounts receivable rose to $12.4m from $9.9m.
NAI reported no consolidated debt outstanding. It had a new $10.0m Wells Fargo working-capital line, undrawn, and stated that $10.5m was available under its credit facilities. Management said cash, operating cash flows and available facilities should fund working capital and capital expenditures for at least 12 months. Total assets were $65.1m and total liabilities $15.5m at March 31, 2016.
Material changes and notable items
- Revenue growth reflected higher contract-manufacturing shipments and the transition to direct beta-alanine sales. Contract manufacturing increased 41% in the quarter and 21% year to date; licensing-segment revenue increased 141% and 242%, respectively.
- Gross-margin improvement was attributed mainly to better manufacturing throughput and lower per-unit costs, partly offset by product and material mix and lower euro exchange rates. SG&A rose 27% in the quarter and 25% year to date, including higher compensation, litigation and patent-compliance, and sales and marketing costs.
- Other income included a one-time $1.6m pretax gain from selling the former San Marcos headquarters. The company purchased a new headquarters in Carlsbad and incurred higher capital expenditures.
- Foreign exchange affected results: the average euro exchange rate was 1.11 EUR/USD in the first nine months versus 1.34 a year earlier. Forward contracts designated as cash-flow hedges had a $0.514m net liability at March 31, 2016.
- Customer concentration remained high: the two historically largest manufacturing customers represented 66% of contract-manufacturing sales for the first nine months, up from 61%. One customer alone represented 51% of that segment’s sales. NAI expected concentration to increase marginally during the rest of fiscal 2016.
Outlook, risks and contingencies
NAI provided no specific revenue or earnings guidance. For the remainder of fiscal 2016, management planned to develop manufacturing customer relationships, expand CarnoSyn commercialization and protect its patent rights, and improve operating efficiency and cost management. Management cautioned that interim results are not necessarily indicative of full-year results.
Key risks include dependence on major customers and limited suppliers for certain raw materials, including beta-alanine; shipment timing and foreign-exchange fluctuations; the ability to maintain patent rights and grow direct beta-alanine sales; and manufacturing, regulatory and product-related risks. The Woodbolt patent litigation was dismissed with prejudice in March 2016 under a settlement that granted Woodbolt a license to relevant patents. Patent re-examination proceedings remained pending, and NAI’s litigation against Creative Compounds was ongoing, with a trial date set for September 2017. The company said ordinary-course claims could still result in adverse costs or outcomes.
Investor verification points
- Confirm the intended reporting period: this filing is for fiscal 2016 Q3, not 2015 Q3.
- Assess whether the reported earnings growth is sustainable without the $1.6m headquarters-sale gain and given the change from royalty revenue to direct raw-material sales.
- Track inventory growth, operating cash conversion, capital spending and collections; inventory growth used $7.2m of cash in the nine-month period.
- Monitor customer concentration, beta-alanine supply availability, patent proceedings and the scope and economics of the Woodbolt license settlement.
- Reconcile the filing’s share-repurchase disclosures: the quarterly table reports 16,900 shares at an average $6.93, while the narrative states $329,000 of quarterly repurchases; the filing also reports $329,000 as the nine-month total.